Search

2022 FEB 12 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- New study results on personality disorders have been published. According to news [...]

Byline: Yash Ved The Drug Technical Advisory Board (DTAB) has recommended to the Union health ministry to examine the issue of safety of fixed dose combination(FDC) of flupenthixol+melitracen for human [...]

Specifically, we examined whether NAc injections of NPY might reverse behavioral deficits caused by reduced dopamine signaling due to systemic dopamine receptor antagonism. Keywords: Winston-Salem; State:North Carolina; United States; North and Central America; Basal Ganglia; Biogenic Amines; Brain Research; Catecholamines; Central Nervous System; Dopamine; Flupenthixol; Health and Medicine; Nerve Tissue Proteins; Neuropeptide Y; Neuropeptides; Nucleus Accumbens; Organic Chemicals; Peptides and Proteins; Prosencephalon; Proteins; Telencephalon; Thioxanthenes EN Winston-Salem State:North Carolina United States North and Central America Basal Ganglia Biogenic Amines Brain Research Catecholamines Central Nervous System Dopamine Flupenthixol Health and Medicine Nerve Tissue Proteins Neuropeptide Y Neuropeptides Nucleus Accumbens Organic Chemicals Peptides and Proteins Prosencephalon Proteins Telencephalon Thioxanthenes 3989 3989 1 03/23/23 20230317 NES 230317 2023 MAR 17 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Investigators discuss new findings in Proteins - Neuropeptides. [Extracted from the article]

Recent studies have shown that dibenzocyclooctadiene lignans may reverse P-glycoprotein-mediated multidrug resistance (Pgp-MDR) in cancer cells; however, the mechanism of action remains unknown. Through screening of herbs, we found that schisandrol A (SCH) isolated from Fructus Schisandrae (the dried fruit of SCHISANDRA CHINENSIS (Turcz.) Baill.) sensitized Pgp-MDR HepG2-DR cells by interfering with the function of Pgp-substrate complexes. In Pgp-MDR cells, SCH enhanced the cytotoxicity of cancer drugs that are Pgp substrates and restored vinblastine-induced G 2/M arrest without lowering Pgp expression. SCH increased cellular retention of Pgp substrates such as rhodamine 123. In Pgp-overexpressing membrane preparations, SCH stimulated basal Pgp-ATPase thus showing some substrate-like function. However, SCH was not a competitive inhibitor for verapamil or progesterone and decreased their K m. In the presence of substrates, SCH decreased the reactivity between Pgp and the monoclonal antibody UIC-2 which is normally increased with active substrate-Pgp complexes. The labeling of active Pgp transport sites by [ 125I]-iodoarylazidoprazosin was partially blocked by SCH. SCH did not affect the activity of the mutant Pgp F983A suggesting that SCH acted differently than the thioxanthene type of Pgp allosteric inhibitors. Our results suggest that SCH acts by affecting the normal formation and functioning of the Pgp-substrate complexes. [ 125I]IAAP:[ 125I]-iodoarylazidoprazosin MDR:multidrug resistance Pgp:P-glycoprotein PI:propidium iodide Rh-123:rhodamine 123 SCH:schisandrol A SRB:sulforhodamine B [ABSTRACT FROM AUTHOR]

By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on Thioxanthenes have been presented. According to news reporting out of Aichi, Japan, by NewsRx [...]

The article describes the case of a 21-year-old man who developed oculogyric crisis associated with paroxysmal auditory pseudohallucinations while undergoing zuclopenthixol therapy.